Annual report for Parmax Pharma Ltd. for FY-2019
03-06-2019
Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Dear Sirs, In terms of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached a copy of the advertisement clipping of Extract of Standalone Audited Financial Results of the Company for the year ended 31st March, 2019 published in Financial Express (English daily) and Financial Express (Gujarati daily) dated 1st June, 2019 which were approved at the Board Meeting of the Company held on Thursday, the 30th day of May, 2019. Thanking You,01-06-2019
Parmax Pharma Ltd - 540359 - Results For Quarter And Financial Year Ended 31St March, 2019
Dear Sirs, Further to our letter dated 23rd May, 2019 and pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirement), Regulations 2015 we wish to inform you that the Board of Directors of the Company in its meeting held today, i.e. 30th May, 2019, have considered and approved the Audited standalone financial results for the quarter and financial year ended 31St March, 2019. '' Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement), Regulations 2015, we enclose herewith: 1. Audited Standalone Financial Results for the quarter and year ended 31st March, 2019. 2. Independent Auditor's Report on the Audited Financial Results for the quarter and year ended 31St March, 2019. 3. Statement on Impact of Audit Qualification on Standalone Financial results for the year ended March 31, 2019 in compliance with SEBI Circular No. ClR/CFD/CMD/56/2016 Dated May 27, 2016.30-05-2019
Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2019 ,inter alia, to consider and approve Dear Sir/Madam, With reference to the captioned subject, we would like to inform you that the Meeting of the Board of Directors of Parmax Pharma Limited will be held on Thursday, 30th May, 2019 at 2.00 PM at the registered office of the company inter alia to consider, approve the Audited Financial Results for the year ended 31st March, 2019 and to discuss any other matter with the permission of Board. Under our letter dated 3rd April, 2019, we had communicated closure of trading window in respect of the Company from 3rd April, 2019 till 48 hours after public announcement of the Audited Financial Results for the year ended 31st March, 2019. Consequently, the Trading Window will remain closed till 1st June, 2019. You are requested to kindly take the above information on your record. Thanking you.23-05-2019
Parmax Pharma Ltd - 540359 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayParmax Pharma Ltd 2CININE240T01014 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 5 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: YASH J. VORA Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: cs@parmaxpharma.com Name of the Chief Financial Officer: KEYUR D. VORA Designation: CHIEF FINANCIAL OFFICER EmailId: keyurvora@parmaxpharma.com Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.30-04-2019
Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996
We herewith enclose a Certificate dated 24th April, 2019 under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March 2019 received from M/s. Purva Shregistey India Private Limited, Registrar and Share Transfer Agent of our company. Thanking you27-04-2019
Parmax Pharma Ltd - 540359 - Disclosure Under SEBI (LODR) Regulations, 2015 - Regarding Revocation Of Resignation From The Post Of Chief Financial Officer Tendered By Mr. Keyur Vora.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, and in continuation of our Corporate Announcement dated 17th March, 2019 we wish to inform you that Mr. Keyur Vora has revoked his resignation and he is continuing as a Chief Financial Officer of the Company. Board of Directors have appreciated his decision and took note of the same in their meeting held today. Kindly take note of the same in your records. Thanking You,26-04-2019
Parmax Pharma Ltd - 540359 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2019.
Dear Sir/Madam, Pursuant to the provisions of Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the certificate received from Mr. Samsad Alam Khan, Practicing Company Secretary, for the half-year ended 31st March, 2019 confirming the compliance of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is for your kind information and record please. Kindly acknowledge the receipt.24-04-2019
Parmax Pharma Ltd - 540359 - Shareholding for the Period Ended March 31, 2019
Parmax Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here18-04-2019